ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0518

Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients

Santos Castañeda1, Alejandra Ramos-Manzano2, Ines Sanchez-Abad3, Miren Uriarte-Ecenarro4, M. Paula Alvarez-Hernandez4, Esther San-Antonio4, Esther Vicente-Rabaneda5 and Ana Urzainqui4, 1Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 2Hospital Unversitario de la Princesa, Madrid, Madrid, Spain, 3Hospitla de la Princesa, Madrid, Spain, 4Hospital de la Princesa, Madrid, Madrid, Spain, 5Hospital Universitario de La Princesa, Madrid, Spain

Meeting: ACR Convergence 2025

Keywords: Adhesion, Adhesion molecules, innate immunity, interferon, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0506–0521) Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Primary Sjögren’s Syndrome (pSS) is an autoimmune disease characterized by lymphocytic infiltration of exocrine glands and systemic manifestations including cutaneous and renal involvement. Phagocytes–monocytes, neutrophils, and dendritic cells– are innate immune cells playing crucial roles in both innate defence and modulation of adaptive immunity. Dysregulation of these cells in pSS has been linked to altered inflammatory response, although the mechanisms driving disease progression remain unclear. PSGL-1 is a leukocyte adhesion molecule and a checkpoint for the immune system. High expression level of HLA-DR is a sign of immune activation. Additionally, higher production of IFNα has been related to pSS pathogenesis

Methods: We obtained the peripheral blood of 44 pSS patients and 26 healthy donors (HD). The percentage of cells expressing PSGL-1, HLA-DR and IFNα mean fluorescence intensity (MFI) was analysed by flow cytometry in neutrophils, monocytes (both classical and non-classical), and plasmacytoid dendritic cells (pDC). Statistical differences between HD and patients were calculated using Mann-Whitney U test or Student’s T-test. Association of the different variables with the presence of the disease was assessed by binary logistic regression (BLR). Then, we performed its receiver operating characteristic (ROC) curves. Statistical significance was set at p< 0.05. Statistical analyses were performed using SPSS 25.0 and GraphPad Prism 8 software.

Results: Compared to HD, the percentage of HLA-DR-expressing cells was increased in neutrophils, monocytes, and pDC of pSS patients. The expression level was higher in pDC and monocytes, suggesting constitutive immune activation in pSS patients. The percentage of neutrophils and pDCs expressing PSGL-1 and PSGL-1’s MFI of non-classical monocytes were reduced compared to HD. This reduction may contribute to higher leukocyte activation. However, the expression level of PSGL-1 in non-classical monocytes was increased. Regarding IFN-α, we found an elevated percentage of neutrophils, classical monocytes and pDC producing IFNα in pSS patients and reduced percentage of non-classical monocytes. BLR analyses identified percentage of neutrophils expressing HLA-DR (79.6% sensitivity, 56.7% specificity and AUC 0.756), percentage of pDC expressing IFNα (92.7% sensitivity, 13.6% specificity and AUC 0.634) and ratio of conventional dendritic cells (cDC) and pDC (83.7% sensitivity, 60% specificity and AUC 0.75) as potential biomarkers for pSS diagnosis.

Conclusion: Our findings underscore an important role of phagocytes in maintaining chronic immune activation in pSS patients. The altered expression of these molecules in innate cell populations might contribute to disease’s pathogenesis. The results contribute to our understanding of phagocyte involvement in pSS and offer potential new avenues for diagnostic strategies.


Disclosures: S. Castañeda: None; A. Ramos-Manzano: None; I. Sanchez-Abad: None; M. Uriarte-Ecenarro: None; M. Alvarez-Hernandez: None; E. San-Antonio: None; E. Vicente-Rabaneda: None; A. Urzainqui: None.

To cite this abstract in AMA style:

Castañeda S, Ramos-Manzano A, Sanchez-Abad I, Uriarte-Ecenarro M, Alvarez-Hernandez M, San-Antonio E, Vicente-Rabaneda E, Urzainqui A. Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/deregulation-of-psgl-1-hla-dr-and-ifn%ce%b1-expression-in-peripheral-innate-immune-cells-of-primary-sjogren-syndrome-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deregulation-of-psgl-1-hla-dr-and-ifn%ce%b1-expression-in-peripheral-innate-immune-cells-of-primary-sjogren-syndrome-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology